Jacobs Levy Equity Management
OTLK icon

Jacobs Levy Equity Management’s Outlook Therapeutics OTLK Stock Holding History

Jacobs Levy Equity Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,850
Closed -$159K – 1058
2021
Q4 		$159K Sell
5,850
-3,075
-34% -$110K ﹤0.01% 946
2021
Q3 		$387K Hold
8,925
– – ﹤0.01% 895
2021
Q2 		$444K Hold
8,925
– – ﹤0.01% 885
2021
Q1 		$402K Sell
8,925
-4,904
-35% -$188K ﹤0.01% 893
2020
Q4 		$360K Sell
13,829
-908
-6% -$19K ﹤0.01% 892
2020
Q3 		$212K Buy
+14,737
New +$328K ﹤0.01% 956

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VF
Vista Finance Clayton, Missouri $179M AUM 18.59% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jacobs Levy Equity Management's OTLK Position: Q1 2022 in Review

Jacobs Levy Equity Management sold out of Outlook Therapeutics (OTLK) in Q1 2022, closing a stake of 5,850 shares — an estimated $159K sold.

Jacobs Levy Equity Management first reported a position in OTLK in Q3 2020 and held it in 6 quarters. The position peaked at $444K in Q2 2021. 73 funds tracked by Wall St. Rank hold OTLK as of Q1 2022.

  • Jacobs Levy Equity Management reported no remaining Outlook Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 5,850 Outlook Therapeutics shares in Q1 2022, an estimated $159K.
  • Jacobs Levy Equity Management first reported a position in Outlook Therapeutics in Q3 2020 and held it in 6 quarters.
  • Jacobs Levy Equity Management's Outlook Therapeutics position peaked at $444K in Q2 2021.
  • 73 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2022, filed 16 May 2022.